Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
National Institute of Mental Health (NIMH) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00024622 |
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine neurochemistry and blood flow in normal volunteers, persons with Parkinson's disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Jose Apud, M.D., Ph.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H(2)O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. Using analysis of Ki, we compare Ki across subject groups and relate the findings to rCBF. Cerebral findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 "Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings," PI: Daniel Weinberger, M.D.). We also draw comparisons between subjects with inherited vs. sporadic Parkinson's disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans....
Condition |
---|
Parkinson's Disease |
Study Type: | Observational |
Official Title: | Positron Emission Tomography (PET) Scanning in Dopamine Disorders: Parkinson's Disease and Schizophrenia |
Estimated Enrollment: | 360 |
Study Start Date: | September 2001 |
Estimated Primary Completion Date: | July 2004 (Final data collection date for primary outcome measure) |
This is a positron emission tomography (PET) study of regional cerebral dopamine neurochemistry and blood flow in normal volunteers, patients with Parkinson's disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Jose Apud, M.D., Ph.D. Using PET with 6-[F-18] Fluoro-L-dopa (FDOPA) and (15)0-H(2)O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. Using analysis of Ki, we compare Ki across subject groups and relate the findings to rCBF.
Cerebral findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 "Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings," PI: Daniel Weinberger, M.D.). We also draw comparisons between subjects with inherited vs. sporadic Parkinson's disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
PARKINSONS DISEASE:
SCHIZOPHRENIA:
HEALTHY VOLUNTEERS:
EXCLUSION CRITERIA:
PARKINSONS DISEASE:
HEALTHY VOLUNTEERS:
Contact: Aideen McInerney-Leo | (301) 402-0160 | amcinern@nhgri.nih.gov |
Contact: Jasmin Salloum, Ph.D. | (301) 435-7645 | js733c@nih.gov |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 |
Study ID Numbers: | 010232, 01-M-0232 |
Study First Received: | September 23, 2001 |
Last Updated: | August 24, 2009 |
ClinicalTrials.gov Identifier: | NCT00024622 History of Changes |
Health Authority: | United States: Federal Government |
Familial Genetic Symptomatic Equivocally Affected 18F-Fluoro-L-dopa O-15 Labelled Water Carbidopa Adult |
Schizophrenia Parkinson's Disease Parkinson's Disease PD Parkinson Healthy Control HV Normal Control |
Levodopa Ganglion Cysts Basal Ganglia Diseases Carbidopa Central Nervous System Diseases Healthy Brain Diseases Neurodegenerative Diseases |
Schizophrenia Dopamine Parkinson Disease Movement Disorders Dihydroxyphenylalanine Dopamine Agents Parkinsonian Disorders |
Movement Disorders Parkinson Disease Nervous System Diseases Basal Ganglia Diseases |
Central Nervous System Diseases Parkinsonian Disorders Neurodegenerative Diseases Brain Diseases |